Study guide

Antibody Screen, Identification, DAT, Elution, and Enhancement Methods

ASCP MLT Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 ASCP MLT Exam Overview and Laboratory Operations

Current Exam Facts and CAT Scoring Eligibility Routes and MLT Study Strategy Laboratory Safety, Quality, and Compliance Lab Math, Instrumentation Troubleshooting, and Result Verification

2 Chemistry, Urinalysis, and Body Fluid Interpretation

Chemistry Calculations, Acid-Base, and Electrolytes Renal, Liver, Endocrine, Enzyme, TDM, and Toxicology Patterns Chemistry QC, Interferences, Specimen Handling, and Result Correlation Urinalysis Microscopy and Body Fluid Decision Patterns

3 Hematology and Hemostasis

CBC, RBC Indices, Reticulocytes, and Anemia Patterns Leukocyte Morphology, Differentials, and Disease Clues Platelet Findings, Coagulation Pathways, PT/aPTT, and Hemostasis Testing Hematology Quality Flags, Specimen Issues, and Smear Review Decisions

4 Blood Banking and Transfusion Practice

ABO/Rh Typing: Forward, Reverse, and Discrepancies Antibody Screen, Identification, DAT, Elution, and Enhancement Methods Compatibility Testing, Crossmatch, Components, and Storage Transfusion Reactions, HDFN, Donor/Product Decisions, and Safety Workflow

5 Microbiology Workups and Susceptibility Reasoning

Specimen Quality, Safety, and Culture Setup Gram Stain, Media, and Biochemical Identification Mycology, Mycobacteriology, Virology, and Parasitology Essentials Antimicrobial Susceptibility, QC, and Postanalytic Reporting

6 Immunology, Integrated Cases, and Final Review

Immunology Principles, Autoimmune Testing, Infectious Serology, and Molecular/Serologic Methods Transplant, Complement, Immunoglobulins, and Result Interpretation Integrated Case Reasoning Across Departments Final Seven-Day Review, CAT Pacing, and Remediation

Antibody Screen, Identification, DAT, Elution, and Enhancement Methods

Key Takeaways Explain This Topic AI

A positive antibody screen is a signal to identify clinically significant unexpected antibodies before routine compatible red cell release.

A negative autocontrol with a positive screen suggests an alloantibody; a positive autocontrol or positive DAT raises concern for autoantibody, drug effect, transfusion reaction, or in vivo coating.

DAT detects red cells coated in vivo with IgG and/or complement; the antibody screen detects free antibody in patient plasma or serum.

Elution is useful when antibody is bound to red cells, such as in hemolytic disease of the fetus and newborn or a delayed hemolytic transfusion reaction.

Enhancement and enzyme methods change reaction strength, so the exam expects pattern recognition rather than memorized tube steps.

Last updated: May 2026

Screening versus identifying antibodies

An antibody screen uses reagent red cells to detect unexpected antibodies in patient plasma or serum. The screen answers a yes-or-no safety question: is there evidence of an antibody that could matter for transfusion or pregnancy? A positive screen is not the final answer. It triggers antibody identification, history review, and selection of compatible red cell units.

An antibody identification panel compares patient plasma against a larger set of reagent cells with known antigen profiles. The exam does not usually ask you to perform every bench step. It asks whether you can connect reaction patterns to likely specificities and safe unit selection.

Finding What it suggests MLT decision pattern

Screen positive, autocontrol negative Alloantibody is likely Identify antibody and provide antigen-negative, crossmatch-compatible red cells

Screen positive, autocontrol positive Autoantibody, recent transfusion, drug effect, or antibody coating patient cells Check DAT and history; do not assume a simple alloantibody only

All panel cells reactive at AHG, autocontrol positive Warm autoantibody pattern is possible Consider adsorption workup by reference process and evaluate for underlying alloantibodies

Reaction only with antigen-positive cells Specific alloantibody is likely Confirm with rule-out and select antigen-negative units

Historical clinically significant antibody but current screen negative Antibody may have evanesced Honor history and issue antigen-negative units

Clinically significant antibodies usually react at 37 C or the antiglobulin phase and can cause hemolytic transfusion reactions or hemolytic disease of the fetus and newborn. Rh, Kell, Kidd, Duffy, and S/s antibodies are high-yield. Lewis, P1, M, and cold autoantibodies are often less clinically significant when only cold-reactive, but exceptions and local policy matter.

Panel logic the exam rewards

Start with phase, strength, and autocontrol. Immediate-spin or room-temperature reactions suggest cold-reactive antibodies, ABO problems, or rouleaux. AHG-only reactions suggest IgG antibodies such as Rh, Kell, Kidd, Duffy, or S/s. A stronger reaction with homozygous antigen expression can reflect dosage, especially with Kidd, Duffy, MNS, and some Rh antibodies.

Then compare reactive cells to antigen profiles. If every K-positive cell reacts and every K-negative cell is nonreactive, anti-K is plausible. If an antibody screen is positive because of anti-Fya, the transfusion answer is Fy(a-) red cells, not merely ABO-compatible red cells.

Many programs teach a rule-of-three confirmation pattern: at least three antigen-positive cells react and at least three antigen-negative cells do not react. The exam point is not the arithmetic alone. The point is that an antibody should be supported by a defensible pattern, not by one convenient panel cell.

DAT and elution

The direct antiglobulin test (DAT) detects IgG and/or complement already attached to the patient's red cells in vivo. It is different from the antibody screen, which tests free antibody in plasma or serum.

Test Sample focus High-yield use

Antibody screen Patient plasma or serum plus reagent red cells Finds unexpected free antibodies before transfusion

Autocontrol Patient plasma or serum plus patient red cells Helps separate alloantibody pattern from autoantibody or in vivo coating clues

DAT Patient red cells plus antiglobulin reagent Detects in vivo coating in HDFN, autoimmune hemolysis, drug-induced hemolysis, or transfusion reaction

Eluate testing Antibody removed from coated patient red cells Identifies antibody bound to cells in HDFN or delayed hemolytic transfusion reaction

A positive DAT can be due to IgG, complement, or both. Anti-IgG positivity is common in warm autoimmune hemolytic anemia and many cases of HDFN. Complement-only positivity can be seen with cold-reactive processes. A post-transfusion patient with a new positive DAT and falling hemoglobin raises concern for a delayed hemolytic reaction, especially with Kidd antibodies, which are known for becoming undetectable and then returning after exposure.

Elution is most useful when the important antibody is stuck to red cells. In HDFN, an eluate from neonatal red cells can identify maternal IgG coating the infant cells. In a delayed hemolytic reaction, eluate testing can reveal the antibody coating transfused donor cells.

Enhancement and enzyme methods

Enhancement media and enzymes are tools for changing antibody-antigen reaction visibility. The MLT exam usually asks what pattern they create or which antibodies are affected.

Method High-yield effect Exam caution

Low ionic strength solution (LISS) Speeds IgG uptake and shortens incubation Used for many routine antibody detection workflows

Polyethylene glycol (PEG) Increases sensitivity for IgG antibodies Can increase nonspecific reactivity; follow method limits

Albumin Reduces zeta potential Less sensitive than some modern methods but still a classic concept

Enzyme-treated cells Enhance Rh, Kidd, Lewis, P1, and I reactivity Destroy or weaken many Duffy and MNS antigens such as Fya, Fyb, M, and N

Thiol reagents such as dithiothreitol Denature Kell system antigens and disrupt IgM Useful in selected complex workups, such as daratumumab interference protocols by policy

For exam decision-making, enzymes are a pattern amplifier. If a reaction disappears with enzyme-treated cells, think Duffy or MNS. If it becomes stronger, think Rh, Kidd, Lewis, P1, or I. Do not use an enzyme result in isolation; combine it with phase, autocontrol, patient history, and panel antigen profiles.

The safe transfusion answer

When a clinically significant antibody is identified, select red cell units negative for the corresponding antigen and compatible by the required crossmatch method. If specificity is unresolved and the transfusion is not emergent, routine release should wait. If the patient is bleeding and delay is dangerous, emergency-release documentation and physician authorization become part of the workflow.